Saturday, October 3, 2026

Intel +240%, AMD +112%: Global AI Inference Shift Leaves Nvidia Behind in 2026 Rally

Intel has surged 240% year-to-date in 2026 while Nvidia — the world's dominant AI chipmaker — has returned just 15%. The divergence reflects how global AI infrastructure spending is flowing beyond training GPUs into inference-optimised hardware. Markets from Wall Street to Tokyo are repricing chipmakers at the edges of Nvidia's ecosystem.

LM Salvado
LM Salvado

May 12, 2026

Intel +240%, AMD +112%: Global AI Inference Shift Leaves Nvidia Behind in 2026 Rally
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Intel stock has surged 240% year-to-date in 2026.1 AMD is up 112%. Micron Technology has gained 162%.1 Nvidia, the dominant AI chip supplier to data centres across the US, Europe, and Asia, has returned just 15%.1

The gap reflects a structural shift in global AI spending. Nvidia's GPU dominance — cemented through contracts with hyperscalers from Amazon to Alibaba — is established and priced in. Markets are now repricing companies on the edges of Nvidia's ecosystem.

AI inference is the driver. Training a model favours Nvidia's high-end GPUs. Running that model — serving queries to billions of users globally — rewards efficiency and lower cost-per-query. CPUs from Intel and AMD compete strongly on inference, particularly where GPU-level parallelism is unnecessary.

AMD doubled its server CPU total addressable market forecast.1 That revision signals real demand, not theoretical opportunity. Across data centres in Frankfurt, Singapore, and Virginia, operators are reconsidering CPU-based inference for cost-sensitive workloads.

Micron's 162% gain reflects its position as a critical supplier to all sides.1 High-bandwidth memory is essential whether a workload runs on a GPU or CPU. Micron ships to Nvidia, Intel, and the hyperscalers building AI infrastructure across every major market. Its rally reflects broad spending, not a single architecture bet.

The pattern has precedent. In the PC era, dominant platform vendors underperformed once their position was priced in. Re-rating moved to component suppliers and adjacent competitors gaining share — a dynamic visible from Seoul's DRAM manufacturers to Silicon Valley's fabless designers.

Nvidia's +15% is not a failure. It reflects a stock already valued for market dominance. Intel's +240% reflects a market repricing a company that lost ground for years and has found renewed relevance in an inference-heavy global AI landscape.

The thesis will be tested in IDC and Gartner server market share reports through end of 2026.1 If AMD's CPU share gains appear in quarterly data, the bifurcation holds. If Nvidia extends its GPU lead into inference workloads globally, the Intel and AMD re-rating may prove temporary.

For now, global semiconductor markets are voting that AI infrastructure build-out benefits the full supply chain — but that Nvidia's upside has already been spent.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com